Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFFITOPE Vaccines for PCSK9 in Healthy Subjects
NCT02508896Phase 1Completed
- Sponsor
- AFFiRiS
- Start
- Jul 2015
- Primary completion
- May 2016
- Modality
- Split/Subunit Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in hypercholesterolemia comparing AFFITOPE AT04A, AFFITOPE AT06A and Placebo (3 arms). Primary endpoint: Serious Adverse Events at 21 months. Started Jul 2015; status: completed.
02
Drugs
AT04AAT06A
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT02508896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02508896.